New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
05:28 EDTITMNInterMune downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded InterMune (ITMN) to Neutral citing valuation after the stock rallied on a Bloomberg report of takeover interest. Goldman continues to expect InterMune's Esbriet for orphan lung disease will receive FDA approval on or before the November 23 action date. The firm has a $49 price target for shares, which closed yesterday up 14% to $52.06.
News For ITMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ITMN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use